Tailoring Ovarian Cancer Treatment: Implications of <i>BRCA1/2</i> Mutations.

Cancers (Basel) · 2019 · PMC6468364 · PMID 30909618

Europe PMC DOI

hedged sentence

0.0980

closest p · 2.0× alpha

0.0980

boldest claim

The sentences

showed a trendp = 0.098so close (0.05 < p ≤ 0.1)

A meta-analysis where the prior cohort study was excluded, showed a trend towards reduced risk of OC with tubal-ligation in BRCA 1 mutation carriers (odds ratio 0.69, p = 0.098), but not in BRCA 2 mutation carriers (odds ratio 0.73, p = 0.33), likely due to small number [ 42 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.